格列齐特:修订间差异
外观
删除的内容 添加的内容
小 →top |
Add 1 book for verifiability (20220217sim)) #IABot (v2.0.8.6) (GreenC bot |
||
第46行: | 第46行: | ||
| StdInChIKey = BOVGTQGAOIONJV-UHFFFAOYSA-N |
| StdInChIKey = BOVGTQGAOIONJV-UHFFFAOYSA-N |
||
}} |
}} |
||
'''格列齐特'''({{lang-en|Gliclazide}}),商品名为'''达美康'''。是一种[[磺酰脲类]]口服[[抗糖尿病药]]。 <ref name="pmid2106423">{{cite journal |pages=109–14 |doi=10.1016/0168-8227(90)90020-T |title=Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds |year=1990 |last1=Ballagi-Pordány |first1=György |last2=Köszeghy |first2=Anna |last3=Koltai |first3=Mária-Zsófia |last4=Aranyi |first4=Zoltán |last5=Pogátsa |first5=Gábor |journal=Diabetes Research and Clinical Practice |volume=8 |issue=2 |pmid=2106423}}</ref><ref>{{cite journal |pages=722–30 |doi=10.1016/j.metabol.2006.01.019 |title=Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation |year=2006 |last1=Shimoyama |first1=Tatsuhiro |last2=Yamaguchi |first2=Shinya |last3=Takahashi |first3=Kazuto |last4=Katsuta |first4=Hidenori |last5=Ito |first5=Eisuke |last6=Seki |first6=Hiroyuki |last7=Ushikawa |first7=Kenji |last8=Katahira |first8=Hiroshi |last9=Yoshimoto |first9=Katsuhiko |last10=Ohno |first10=Hideki |last11=Nagamatsu |first11=Shinya |last12=Ishida |first12=Hitoshi |journal=Metabolism |volume=55 |issue=6 |pmid=16713429|display-authors=8 }}</ref>. 格列齐特可以防止因高血糖引起的[[细胞凋亡]],保护人体的[[胰岛|胰岛β细胞]]。<ref>{{cite journal |pages=234–8 |doi=10.1002/dmrr.680 |title=Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose |year=2007 |last1=Del Guerra |first1=S |last2=Grupillo |first2=M |last3=Masini |first3=M |last4=Lupi |first4=R |last5=Bugliani |first5=M |last6=Torri |first6=S |last7=Boggi |first7=U |last8=Del Chiaro |first8=M |last9=Vistoli |first9=F |last10=Mosca |first10=F |last11=Del Prato |first11=S |last12=Marchetti |first12=P |journal=Diabetes/Metabolism Research and Reviews |volume=23 |issue=3 |pmid=16952202|display-authors=8 }}</ref> 格列齐特还可以防止因[[2型糖尿病]]导致的[[动脉粥样硬化]](防止动脉脂肪堆积)。<ref>{{cite journal |pages=1906–13 |doi=10.1007/s00125-004-1547-8 |title=Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes |year=2004 |last1=Katakami |first1=N. |last2=Yamasaki |first2=Y. |last3=Hayaishi-Okano |first3=R. |last4=Ohtoshi |first4=K. |last5=Kaneto |first5=H. |last6=Matsuhisa |first6=M. |last7=Kosugi |first7=K. |last8=Hori |first8=M. |journal=Diabetologia |volume=47 |issue=11 |pmid=15565373}}</ref>格列齐特在中国作为一线药物使用,应用极为广泛,而在其他国家却并不常用。Diamicron ( Gliclazide) |
'''格列齐特'''({{lang-en|Gliclazide}}),商品名为'''达美康'''。是一种[[磺酰脲类]]口服[[抗糖尿病药]]。 <ref name="pmid2106423">{{cite journal |pages=109–14 |doi=10.1016/0168-8227(90)90020-T |title=Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds |url=https://archive.org/details/sim_diabetes-research-and-clinical-practice_1990_8_2/page/109 |year=1990 |last1=Ballagi-Pordány |first1=György |last2=Köszeghy |first2=Anna |last3=Koltai |first3=Mária-Zsófia |last4=Aranyi |first4=Zoltán |last5=Pogátsa |first5=Gábor |journal=Diabetes Research and Clinical Practice |volume=8 |issue=2 |pmid=2106423}}</ref><ref>{{cite journal |pages=722–30 |doi=10.1016/j.metabol.2006.01.019 |title=Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation |year=2006 |last1=Shimoyama |first1=Tatsuhiro |last2=Yamaguchi |first2=Shinya |last3=Takahashi |first3=Kazuto |last4=Katsuta |first4=Hidenori |last5=Ito |first5=Eisuke |last6=Seki |first6=Hiroyuki |last7=Ushikawa |first7=Kenji |last8=Katahira |first8=Hiroshi |last9=Yoshimoto |first9=Katsuhiko |last10=Ohno |first10=Hideki |last11=Nagamatsu |first11=Shinya |last12=Ishida |first12=Hitoshi |journal=Metabolism |volume=55 |issue=6 |pmid=16713429|display-authors=8 }}</ref>. 格列齐特可以防止因高血糖引起的[[细胞凋亡]],保护人体的[[胰岛|胰岛β细胞]]。<ref>{{cite journal |pages=234–8 |doi=10.1002/dmrr.680 |title=Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose |year=2007 |last1=Del Guerra |first1=S |last2=Grupillo |first2=M |last3=Masini |first3=M |last4=Lupi |first4=R |last5=Bugliani |first5=M |last6=Torri |first6=S |last7=Boggi |first7=U |last8=Del Chiaro |first8=M |last9=Vistoli |first9=F |last10=Mosca |first10=F |last11=Del Prato |first11=S |last12=Marchetti |first12=P |journal=Diabetes/Metabolism Research and Reviews |volume=23 |issue=3 |pmid=16952202|display-authors=8 }}</ref> 格列齐特还可以防止因[[2型糖尿病]]导致的[[动脉粥样硬化]](防止动脉脂肪堆积)。<ref>{{cite journal |pages=1906–13 |doi=10.1007/s00125-004-1547-8 |title=Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes |year=2004 |last1=Katakami |first1=N. |last2=Yamasaki |first2=Y. |last3=Hayaishi-Okano |first3=R. |last4=Ohtoshi |first4=K. |last5=Kaneto |first5=H. |last6=Matsuhisa |first6=M. |last7=Kosugi |first7=K. |last8=Hori |first8=M. |journal=Diabetologia |volume=47 |issue=11 |pmid=15565373}}</ref>格列齐特在中国作为一线药物使用,应用极为广泛,而在其他国家却并不常用。Diamicron ( Gliclazide) |
||
==药理== |
==药理== |
2022年2月18日 (五) 03:54的版本
臨床資料 | |
---|---|
商品名 | 达美康 |
AHFS/Drugs.com | Micromedex详细消费者药物信息 |
懷孕分級 |
|
给药途径 | 口服 |
ATC碼 | |
法律規範狀態 | |
法律規範 | |
藥物動力學數據 | |
生物半衰期 | 10.4小时 |
识别信息 | |
| |
CAS号 | 21187-98-4 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.040.221 |
化学信息 | |
化学式 | C15H21N3O3S |
摩尔质量 | 323.412 g/mol |
3D模型(JSmol) | |
| |
|
格列齐特(英語:Gliclazide),商品名为达美康。是一种磺酰脲类口服抗糖尿病药。 [1][2]. 格列齐特可以防止因高血糖引起的细胞凋亡,保护人体的胰岛β细胞。[3] 格列齐特还可以防止因2型糖尿病导致的动脉粥样硬化(防止动脉脂肪堆积)。[4]格列齐特在中国作为一线药物使用,应用极为广泛,而在其他国家却并不常用。Diamicron ( Gliclazide)
药理
格列齐特为胰島素增秘剂,通过抑制胰岛β细胞的KATP通道,从而促进胰岛素的释放。
引用
- ^ Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.
- ^ Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.
- ^ Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.
- ^ Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.